October 7, 2024 ESG Data Convergence Initiative GREENPEAK Partners Demonstrates High ESG Commitment with Third Consecutive Participation in the ESG Data Convergence Initiative (EDCI) and Publishes 2024 Principal Adverse Impact Statement (PAI Statement) Linked to Article 8 SFDR Classification of All Funds GREENPEAK Partners, a leading private equity firm committed to sustainable investment, is proud to announce its participation in the ESG Data Convergence Initiative (EDCI) for the third consecutive year, having been involved since the initiative’s inception. This continuous participation underscores the firm’s commitment to standardizing ESG data and driving sustainability in private markets. The ESG Data Convergence Initiative, a global collaboration designed to harmonize ESG reporting across private equity, has become a crucial platform for improving transparency and comparability of ESG metrics. As an earlier contributor of the initiative, GREENPEAK Partners continues to play a key role in shaping how ESG data is used to promote responsible investment practices. “Our continued participation in the ESG Data Convergence Initiative reflects our commitment to integrating sustainability into the core of our investment strategy,” said Daniel Beringer, Managing Partner of GREENPEAK Partners. “By standardising ESG data, we can ensure that investors have clearer insights into the real-world impact of their investments, thereby driving long-term value creation.” In addition, GREENPEAK Partners has also published the Principal Adverse Impact (PAI) statement relating to the year 2023. This statement is directly linked to the firm’s compliance with Article 8 of the Sustainable Finance Disclosure Regulation (SFDR), which classifies all of GREENPEAK Partners’ funds as promoting environmental and/or social characteristics. The PAI Statement, which is available on the the firm’s website, outlines how GREENPEAK assesses and mitigates the principal adverse impacts of its investment decisions on sustainability factors. “The release of the Principal Adverse Impact Statement is a key milestone in our ESG journey,” said Valentina Stadler, Chief ESG Officer of GREENPEAK Partners. “The PAI Statement, aligned with Article 8 of the SFDR, demonstrates how we prioritize both transparency and accountability in managing the sustainability impacts of our investments. It further reinforces our commitment to promoting environmental and social characteristics across all of our funds.” GREENPEAK’s Article 8 SFDR classification means that all its funds integrate ESG factors in their investment strategies, actively promoting positive environmental and social outcomes while adhering to the highest standards of responsible investment. The publication of the PAI Statement is a significant step in enhancing transparency and further advancing the firm’s ESG leadership. To read GREENPEAK Partners’ Principal Adverse Impact Statement, please visit https://www.greenpeak-partners.com/de/esg/. About GREENPEAK PartnersGREENPEAK Partners is a company builder private equity partnership with proven track record and comprehensive expertise in the foundation, development, and expansion of industry leaders. While executing its Buy & Build strategies, GREENPEAK aims to develop industry leaders by virtue of strong partnerships, ESG values, and aligned sustainable interests. All of the firm’s funds are classified under Article 8 of the SFDR, promoting environmental and social characteristics September 11, 2024 PARATUS acquires projodis PARATUS expands its LIS offering, acquiring projodis, Germany’s leading provider of laboratory software solutions in human genetics Munich, Germany, September 9, 2024. GREENPEAK Partners announced today that through their group PARATUS, they have acquired projodis, the leading provider of laboratory information system (LIS) solutions servicing human geneticists in Germany with further presence in Austria and Switzerland. The acquisition is another strategic building block for PARATUS in its mission to become a leading global provider of best-of-breed healthcare IT solutions, focussing on diagnostics, that empower medical service professionals and improve patient care. The decision to acquire projodis was influenced by their strong market position in human genetics and strategic fit within PARATUS’ growing group. “The projodis product portfolio is a perfect complement to that of DB Soft, our LIS provider in Spain,” said Friedrich von Kleist, CEO of PARATUS. “Adding them to our group and aligning them with DB Soft enables us to build a strong LIS Cluster, which significantly advances our LIS technology and portfolio and supports the expansion into new markets while strengthening the whole PARATUS group.” In line with PARATUS’ business strategy, projodis will retain its individual operations and brand identity, emphasizing PARATUS’ commitment to collaboration without losing the renowned market presence of its acquired companies. projodis products and services will continue without disruption in access or customer support. “I’m thrilled we’ve found a strong partner to take the next step in our company’s development,” said Oliver Krause, Founder and Managing Director of projodis. “A driving factor in our decision to join the group was having, through prior work, already experienced the truly collaborative culture of PARATUS.” Krause added, “I’m confident that together we can grow faster, accelerate innovation, and deliver even better services to our clients.” PARATUS’ robust support for its group companies encompasses financial investment, collaborative tendering, and access to shared resources in areas such as finance, marketing, sales, quality management, new market entry, and more. Media Contact For more information or to schedule an interview, please contact: Mr. Friedrich von Kleist, CEO of PARATUSfkleist@paratus-group.com About PARATUS: PARATUS was formed in 2021 with the goal of creating a global group of best-of-breed healthcare IT companies with a strong position in diagnostics that collaborates to deliver state-of-the-art, tailored solutions to medical service providers that improve healthcare services and patient care, boost productivity, and reduce costs. PARATUS is a group of like-minded market leaders that foster growth through collaboration, sharing best practices, and shared services in finance, HR, regulatory, IT security, and more. Headquartered in Munich, Germany, PARATUS is pursuing a long-term growth path, both organically and by adding new partners to its group. Learn more at www.paratus-group.com About projodis: projodis GmbH is the German market leader in advanced laboratory software solutions, specializing in the development and implementation of cutting-edge tools for the management, control, and monitoring of human genetic laboratory processes and consultations. Based in Butzbach, Germany, and founded in 2010, projodis serves the majority of the human genetic departments of university hospitals and leading outpatient genetic laboratories due to a clear focus and understanding of the unique needs of the genetic field. www.projodis.net About GREENPEAK Partners: GREENPEAK Partners is a company builder with a proven track record and comprehensive expertise in the foundation, development, and expansion of industry leaders. While executing its Buy & Build strategies, GREENPEAK aims to develop industry leaders by virtue of strong partnerships, ESG values, and aligned sustainable interests. To date, the GREENPEAK Partners team has built over ten platforms, with annual revenues exceeding €1 billion. www.greenpeak-partners.com September 4, 2024 ALPHALYTIK JOINS CERTANIA GROUP The specialist in pharmaceutical analytical testing becomes part of the CERTANIA family. Berlin/Munich, Sept. 4, 2024—Alphalytik Pharmaservice GmbH, a leading expert in pharmaceutical analytical testing, proudly announces its integration into CERTANIA, a dynamic group specializing in Testing, Inspection, and Certification services. This strategic move marks a significant milestone for Alphalytik, enhancing its capabilities to deliver specialized stability testing and method validation services to a broader range of pharmaceutical clients. Founded in 1995 and headquartered in Berlin, Germany, Alphalytik has built a strong reputation as an independent laboratory specializing in GMP (Good Manufacturing Practice) and FDA (Food and Drug Administration) approved stability testing, method development, and release testing. With a focus on complex drug formulations, including low-dose and hormone preparations, Alphalytik serves a diverse clientele, including some of the world’s leading pharmaceutical companies. The company’s expertise in ensuring the long-term safety and efficacy of pharmaceutical products has made it a trusted partner. By joining CERTANIA, Alphalytik gains access to a powerful platform that will allow it to expand its service offerings and strengthen its position in the pharmaceutical market. This partnership will enable Alphalytik to address the growing demand for specialized pharmaceutical testing services, driven by increasing drug development and regulatory requirements. Dr. Nicolas Schauer has been appointed as the new managing director and Dr. Richard Herzog, the founder of Alphalytik, will continue to support the company in a consulting role, ensuring a seamless transition and continuity in client relationships. “We are excited to join CERTANIA, a group that shares our commitment to excellence in pharmaceutical testing,” said Dr. Richard Herzog, founder of Alphalytik. “This partnership will provide us with the resources and support needed to continue delivering high-quality, reliable services to our clients while also exploring new growth opportunities.” Karsten Xander, CEO and founder of CERTANIA, welcomed Alphalytik to the group, emphasizing the strategic importance of the acquisition. “The addition of Alphalytik significantly strengthens CERTANIA’s position in the pharmaceutical contract research and manufacturing segment. Their expertise in stability and release testing and method validation complements our existing services, and we see great potential for synergy and growth.” CERTANIA’s acquisition of Alphalytik underscores the group’s commitment to expanding its capabilities in the life sciences sector, enhancing its market presence in Germany and beyond. The integration is expected to drive innovation, improve service offerings, and foster significant growth within the CERTANIA group. CERTANIA provides a platform for mid-sized, knowledge-based companies to thrive under one umbrella, maintaining entrepreneurial freedom while benefiting from group resources and support. About Alphalytik: Founded in 1995 and headquartered in Berlin, Germany, Alphalytik Pharmaservice GmbH is a specialized pharmaceutical laboratory offering drug stability testing, method development, and release testing. With a focus on complex analytical needs, Alphalytik serves a diverse clientele, including leading pharmaceutical companies. The company’s expertise and accredited services ensure the long-term safety and efficacy of pharmaceutical products. For more information, visit alphalytik.com. About CERTANIA: Under the umbrella of CERTANIA Holding GmbH, a new global market player is created in the field of Testing, Inspection & Certification as well as scientific, laboratory and compliance services. This group offers medium-sized partners a sustainable home for their life’s work. CERTANIA enables entrepreneurs and owners to further develop their companies with like-minded people, while continuing to preserve their entrepreneurial roots, corporate culture, brand, and values. For more information, visit certania.com August 20, 2024 BIOTEC joins CERTANIA The pioneer in microbiological and aerial hygiene joins the group. Munich/Gütersloh, August 20, 2024. Biotec GmbH, a leading consultancy and environmental laboratory specializing in microbiological hygiene and occupational health, has joined CERTANIA, a dynamic group known for its Testing, Inspection, and Certification services. This strategic integration marks a pivotal moment for Biotec GmbH, enhancing its ability to expand its environmental and hygiene solutions globally. Founded in 1991 and based in Gütersloh, Germany, Biotec GmbH has built a solid reputation over 25 years as a pioneer in aerial hygiene. Its clientele spans across industrial giants and prominent players in the food industry, relying on its expertise for comprehensive air hygiene testing and certification, drinking water analyses, and specialized hygiene training. By joining CERTANIA, Biotec GmbH aligns itself with a robust platform that supports its commitment to excellence. The partnership strengthens Biotec GmbH’s capabilities in optimizing hygiene-sensitive production processes and validating hospital cleaning and disinfection equipment to meet stringent hygiene standards. Under the leadership of the managing directors Dr. Andreas Bermpohl, Jörg Weißer and Frank Weißer, the Biotec management team retains independence while accessing the resources of the larger group, facilitating continued growth and service expansion. “We are thrilled to join CERTANIA, which allows us to amplify our impact in ensuring safe and compliant environments,” said Dr. Andreas Bermpohl, co-founder and managing director of Biotec GmbH. “This partnership not only enhances our service offerings but also reinforces our dedication to delivering high-quality solutions backed by rigorous scientific expertise.” Moritz Gruber, CEO and managing shareholder of CERTANIA, welcomes Biotec and extends the invitation to join this unique group to other entrepreneurs and owners of companies in the field of scientific, laboratory, and compliance services: “We provide an opportunity to put their company into a future-proof structure. It is our fundamental aim to build a group for the long run, where strong partner companies flourish, while retaining their identity. Biotec’s renowned expertise in microbiological hygiene perfectly complements CERTANIA’s focus on environmental and regulatory services. Together, we are well-positioned to support industries in maintaining safety and compliance standards amid evolving global challenges like the COVID19 pandemic.” CERTANIA’s ecosystem provides a platform for mid-sized, knowledge-based companies to thrive under one umbrella, maintaining entrepreneurial freedom while benefiting from group resources and support. About Biotec GmbH: Founded in 1991 and based in Gütersloh and Mittweida, Germany, Biotec GmbH is a leading consultancy and environmental laboratory specializing in microbiological hygiene and occupational health. With over 25 years of expertise, we pioneer aerial hygiene solutions for diverse industrial and food industry clients. Our services include air hygiene testing, HVAC system inspections under VDI 6022 standards, and hygiene training. Biotec GmbH is committed to excellence, supporting clients with high-quality services and expert opinions to maintain safe and compliant environments. For more information, visit biotec-gmbh.de About CERTANIA: Under the umbrella of CERTANIA Holding GmbH, a new global market player is created in the field of Testing, Inspection & Certification as well as scientific, laboratory and compliance services. This group offers medium-sized partners a sustainable home for their life’s work. CERTANIA enables entrepreneurs and owners to further develop their companies with like-minded people, while continuing to preserve their entrepreneurial roots, corporate culture, brand, and values. For more information, visit certania.com July 10, 2024 GREENPEAK is proudly looking back to a successful first half-year 2024 We would like to thank all our business partners and our teams and look forward to a fantastic second half of the year. Posts navigation Older posts
September 11, 2024 PARATUS acquires projodis PARATUS expands its LIS offering, acquiring projodis, Germany’s leading provider of laboratory software solutions in human genetics Munich, Germany, September 9, 2024. GREENPEAK Partners announced today that through their group PARATUS, they have acquired projodis, the leading provider of laboratory information system (LIS) solutions servicing human geneticists in Germany with further presence in Austria and Switzerland. The acquisition is another strategic building block for PARATUS in its mission to become a leading global provider of best-of-breed healthcare IT solutions, focussing on diagnostics, that empower medical service professionals and improve patient care. The decision to acquire projodis was influenced by their strong market position in human genetics and strategic fit within PARATUS’ growing group. “The projodis product portfolio is a perfect complement to that of DB Soft, our LIS provider in Spain,” said Friedrich von Kleist, CEO of PARATUS. “Adding them to our group and aligning them with DB Soft enables us to build a strong LIS Cluster, which significantly advances our LIS technology and portfolio and supports the expansion into new markets while strengthening the whole PARATUS group.” In line with PARATUS’ business strategy, projodis will retain its individual operations and brand identity, emphasizing PARATUS’ commitment to collaboration without losing the renowned market presence of its acquired companies. projodis products and services will continue without disruption in access or customer support. “I’m thrilled we’ve found a strong partner to take the next step in our company’s development,” said Oliver Krause, Founder and Managing Director of projodis. “A driving factor in our decision to join the group was having, through prior work, already experienced the truly collaborative culture of PARATUS.” Krause added, “I’m confident that together we can grow faster, accelerate innovation, and deliver even better services to our clients.” PARATUS’ robust support for its group companies encompasses financial investment, collaborative tendering, and access to shared resources in areas such as finance, marketing, sales, quality management, new market entry, and more. Media Contact For more information or to schedule an interview, please contact: Mr. Friedrich von Kleist, CEO of PARATUSfkleist@paratus-group.com About PARATUS: PARATUS was formed in 2021 with the goal of creating a global group of best-of-breed healthcare IT companies with a strong position in diagnostics that collaborates to deliver state-of-the-art, tailored solutions to medical service providers that improve healthcare services and patient care, boost productivity, and reduce costs. PARATUS is a group of like-minded market leaders that foster growth through collaboration, sharing best practices, and shared services in finance, HR, regulatory, IT security, and more. Headquartered in Munich, Germany, PARATUS is pursuing a long-term growth path, both organically and by adding new partners to its group. Learn more at www.paratus-group.com About projodis: projodis GmbH is the German market leader in advanced laboratory software solutions, specializing in the development and implementation of cutting-edge tools for the management, control, and monitoring of human genetic laboratory processes and consultations. Based in Butzbach, Germany, and founded in 2010, projodis serves the majority of the human genetic departments of university hospitals and leading outpatient genetic laboratories due to a clear focus and understanding of the unique needs of the genetic field. www.projodis.net About GREENPEAK Partners: GREENPEAK Partners is a company builder with a proven track record and comprehensive expertise in the foundation, development, and expansion of industry leaders. While executing its Buy & Build strategies, GREENPEAK aims to develop industry leaders by virtue of strong partnerships, ESG values, and aligned sustainable interests. To date, the GREENPEAK Partners team has built over ten platforms, with annual revenues exceeding €1 billion. www.greenpeak-partners.com September 4, 2024 ALPHALYTIK JOINS CERTANIA GROUP The specialist in pharmaceutical analytical testing becomes part of the CERTANIA family. Berlin/Munich, Sept. 4, 2024—Alphalytik Pharmaservice GmbH, a leading expert in pharmaceutical analytical testing, proudly announces its integration into CERTANIA, a dynamic group specializing in Testing, Inspection, and Certification services. This strategic move marks a significant milestone for Alphalytik, enhancing its capabilities to deliver specialized stability testing and method validation services to a broader range of pharmaceutical clients. Founded in 1995 and headquartered in Berlin, Germany, Alphalytik has built a strong reputation as an independent laboratory specializing in GMP (Good Manufacturing Practice) and FDA (Food and Drug Administration) approved stability testing, method development, and release testing. With a focus on complex drug formulations, including low-dose and hormone preparations, Alphalytik serves a diverse clientele, including some of the world’s leading pharmaceutical companies. The company’s expertise in ensuring the long-term safety and efficacy of pharmaceutical products has made it a trusted partner. By joining CERTANIA, Alphalytik gains access to a powerful platform that will allow it to expand its service offerings and strengthen its position in the pharmaceutical market. This partnership will enable Alphalytik to address the growing demand for specialized pharmaceutical testing services, driven by increasing drug development and regulatory requirements. Dr. Nicolas Schauer has been appointed as the new managing director and Dr. Richard Herzog, the founder of Alphalytik, will continue to support the company in a consulting role, ensuring a seamless transition and continuity in client relationships. “We are excited to join CERTANIA, a group that shares our commitment to excellence in pharmaceutical testing,” said Dr. Richard Herzog, founder of Alphalytik. “This partnership will provide us with the resources and support needed to continue delivering high-quality, reliable services to our clients while also exploring new growth opportunities.” Karsten Xander, CEO and founder of CERTANIA, welcomed Alphalytik to the group, emphasizing the strategic importance of the acquisition. “The addition of Alphalytik significantly strengthens CERTANIA’s position in the pharmaceutical contract research and manufacturing segment. Their expertise in stability and release testing and method validation complements our existing services, and we see great potential for synergy and growth.” CERTANIA’s acquisition of Alphalytik underscores the group’s commitment to expanding its capabilities in the life sciences sector, enhancing its market presence in Germany and beyond. The integration is expected to drive innovation, improve service offerings, and foster significant growth within the CERTANIA group. CERTANIA provides a platform for mid-sized, knowledge-based companies to thrive under one umbrella, maintaining entrepreneurial freedom while benefiting from group resources and support. About Alphalytik: Founded in 1995 and headquartered in Berlin, Germany, Alphalytik Pharmaservice GmbH is a specialized pharmaceutical laboratory offering drug stability testing, method development, and release testing. With a focus on complex analytical needs, Alphalytik serves a diverse clientele, including leading pharmaceutical companies. The company’s expertise and accredited services ensure the long-term safety and efficacy of pharmaceutical products. For more information, visit alphalytik.com. About CERTANIA: Under the umbrella of CERTANIA Holding GmbH, a new global market player is created in the field of Testing, Inspection & Certification as well as scientific, laboratory and compliance services. This group offers medium-sized partners a sustainable home for their life’s work. CERTANIA enables entrepreneurs and owners to further develop their companies with like-minded people, while continuing to preserve their entrepreneurial roots, corporate culture, brand, and values. For more information, visit certania.com August 20, 2024 BIOTEC joins CERTANIA The pioneer in microbiological and aerial hygiene joins the group. Munich/Gütersloh, August 20, 2024. Biotec GmbH, a leading consultancy and environmental laboratory specializing in microbiological hygiene and occupational health, has joined CERTANIA, a dynamic group known for its Testing, Inspection, and Certification services. This strategic integration marks a pivotal moment for Biotec GmbH, enhancing its ability to expand its environmental and hygiene solutions globally. Founded in 1991 and based in Gütersloh, Germany, Biotec GmbH has built a solid reputation over 25 years as a pioneer in aerial hygiene. Its clientele spans across industrial giants and prominent players in the food industry, relying on its expertise for comprehensive air hygiene testing and certification, drinking water analyses, and specialized hygiene training. By joining CERTANIA, Biotec GmbH aligns itself with a robust platform that supports its commitment to excellence. The partnership strengthens Biotec GmbH’s capabilities in optimizing hygiene-sensitive production processes and validating hospital cleaning and disinfection equipment to meet stringent hygiene standards. Under the leadership of the managing directors Dr. Andreas Bermpohl, Jörg Weißer and Frank Weißer, the Biotec management team retains independence while accessing the resources of the larger group, facilitating continued growth and service expansion. “We are thrilled to join CERTANIA, which allows us to amplify our impact in ensuring safe and compliant environments,” said Dr. Andreas Bermpohl, co-founder and managing director of Biotec GmbH. “This partnership not only enhances our service offerings but also reinforces our dedication to delivering high-quality solutions backed by rigorous scientific expertise.” Moritz Gruber, CEO and managing shareholder of CERTANIA, welcomes Biotec and extends the invitation to join this unique group to other entrepreneurs and owners of companies in the field of scientific, laboratory, and compliance services: “We provide an opportunity to put their company into a future-proof structure. It is our fundamental aim to build a group for the long run, where strong partner companies flourish, while retaining their identity. Biotec’s renowned expertise in microbiological hygiene perfectly complements CERTANIA’s focus on environmental and regulatory services. Together, we are well-positioned to support industries in maintaining safety and compliance standards amid evolving global challenges like the COVID19 pandemic.” CERTANIA’s ecosystem provides a platform for mid-sized, knowledge-based companies to thrive under one umbrella, maintaining entrepreneurial freedom while benefiting from group resources and support. About Biotec GmbH: Founded in 1991 and based in Gütersloh and Mittweida, Germany, Biotec GmbH is a leading consultancy and environmental laboratory specializing in microbiological hygiene and occupational health. With over 25 years of expertise, we pioneer aerial hygiene solutions for diverse industrial and food industry clients. Our services include air hygiene testing, HVAC system inspections under VDI 6022 standards, and hygiene training. Biotec GmbH is committed to excellence, supporting clients with high-quality services and expert opinions to maintain safe and compliant environments. For more information, visit biotec-gmbh.de About CERTANIA: Under the umbrella of CERTANIA Holding GmbH, a new global market player is created in the field of Testing, Inspection & Certification as well as scientific, laboratory and compliance services. This group offers medium-sized partners a sustainable home for their life’s work. CERTANIA enables entrepreneurs and owners to further develop their companies with like-minded people, while continuing to preserve their entrepreneurial roots, corporate culture, brand, and values. For more information, visit certania.com July 10, 2024 GREENPEAK is proudly looking back to a successful first half-year 2024 We would like to thank all our business partners and our teams and look forward to a fantastic second half of the year. Posts navigation Older posts
September 4, 2024 ALPHALYTIK JOINS CERTANIA GROUP The specialist in pharmaceutical analytical testing becomes part of the CERTANIA family. Berlin/Munich, Sept. 4, 2024—Alphalytik Pharmaservice GmbH, a leading expert in pharmaceutical analytical testing, proudly announces its integration into CERTANIA, a dynamic group specializing in Testing, Inspection, and Certification services. This strategic move marks a significant milestone for Alphalytik, enhancing its capabilities to deliver specialized stability testing and method validation services to a broader range of pharmaceutical clients. Founded in 1995 and headquartered in Berlin, Germany, Alphalytik has built a strong reputation as an independent laboratory specializing in GMP (Good Manufacturing Practice) and FDA (Food and Drug Administration) approved stability testing, method development, and release testing. With a focus on complex drug formulations, including low-dose and hormone preparations, Alphalytik serves a diverse clientele, including some of the world’s leading pharmaceutical companies. The company’s expertise in ensuring the long-term safety and efficacy of pharmaceutical products has made it a trusted partner. By joining CERTANIA, Alphalytik gains access to a powerful platform that will allow it to expand its service offerings and strengthen its position in the pharmaceutical market. This partnership will enable Alphalytik to address the growing demand for specialized pharmaceutical testing services, driven by increasing drug development and regulatory requirements. Dr. Nicolas Schauer has been appointed as the new managing director and Dr. Richard Herzog, the founder of Alphalytik, will continue to support the company in a consulting role, ensuring a seamless transition and continuity in client relationships. “We are excited to join CERTANIA, a group that shares our commitment to excellence in pharmaceutical testing,” said Dr. Richard Herzog, founder of Alphalytik. “This partnership will provide us with the resources and support needed to continue delivering high-quality, reliable services to our clients while also exploring new growth opportunities.” Karsten Xander, CEO and founder of CERTANIA, welcomed Alphalytik to the group, emphasizing the strategic importance of the acquisition. “The addition of Alphalytik significantly strengthens CERTANIA’s position in the pharmaceutical contract research and manufacturing segment. Their expertise in stability and release testing and method validation complements our existing services, and we see great potential for synergy and growth.” CERTANIA’s acquisition of Alphalytik underscores the group’s commitment to expanding its capabilities in the life sciences sector, enhancing its market presence in Germany and beyond. The integration is expected to drive innovation, improve service offerings, and foster significant growth within the CERTANIA group. CERTANIA provides a platform for mid-sized, knowledge-based companies to thrive under one umbrella, maintaining entrepreneurial freedom while benefiting from group resources and support. About Alphalytik: Founded in 1995 and headquartered in Berlin, Germany, Alphalytik Pharmaservice GmbH is a specialized pharmaceutical laboratory offering drug stability testing, method development, and release testing. With a focus on complex analytical needs, Alphalytik serves a diverse clientele, including leading pharmaceutical companies. The company’s expertise and accredited services ensure the long-term safety and efficacy of pharmaceutical products. For more information, visit alphalytik.com. About CERTANIA: Under the umbrella of CERTANIA Holding GmbH, a new global market player is created in the field of Testing, Inspection & Certification as well as scientific, laboratory and compliance services. This group offers medium-sized partners a sustainable home for their life’s work. CERTANIA enables entrepreneurs and owners to further develop their companies with like-minded people, while continuing to preserve their entrepreneurial roots, corporate culture, brand, and values. For more information, visit certania.com August 20, 2024 BIOTEC joins CERTANIA The pioneer in microbiological and aerial hygiene joins the group. Munich/Gütersloh, August 20, 2024. Biotec GmbH, a leading consultancy and environmental laboratory specializing in microbiological hygiene and occupational health, has joined CERTANIA, a dynamic group known for its Testing, Inspection, and Certification services. This strategic integration marks a pivotal moment for Biotec GmbH, enhancing its ability to expand its environmental and hygiene solutions globally. Founded in 1991 and based in Gütersloh, Germany, Biotec GmbH has built a solid reputation over 25 years as a pioneer in aerial hygiene. Its clientele spans across industrial giants and prominent players in the food industry, relying on its expertise for comprehensive air hygiene testing and certification, drinking water analyses, and specialized hygiene training. By joining CERTANIA, Biotec GmbH aligns itself with a robust platform that supports its commitment to excellence. The partnership strengthens Biotec GmbH’s capabilities in optimizing hygiene-sensitive production processes and validating hospital cleaning and disinfection equipment to meet stringent hygiene standards. Under the leadership of the managing directors Dr. Andreas Bermpohl, Jörg Weißer and Frank Weißer, the Biotec management team retains independence while accessing the resources of the larger group, facilitating continued growth and service expansion. “We are thrilled to join CERTANIA, which allows us to amplify our impact in ensuring safe and compliant environments,” said Dr. Andreas Bermpohl, co-founder and managing director of Biotec GmbH. “This partnership not only enhances our service offerings but also reinforces our dedication to delivering high-quality solutions backed by rigorous scientific expertise.” Moritz Gruber, CEO and managing shareholder of CERTANIA, welcomes Biotec and extends the invitation to join this unique group to other entrepreneurs and owners of companies in the field of scientific, laboratory, and compliance services: “We provide an opportunity to put their company into a future-proof structure. It is our fundamental aim to build a group for the long run, where strong partner companies flourish, while retaining their identity. Biotec’s renowned expertise in microbiological hygiene perfectly complements CERTANIA’s focus on environmental and regulatory services. Together, we are well-positioned to support industries in maintaining safety and compliance standards amid evolving global challenges like the COVID19 pandemic.” CERTANIA’s ecosystem provides a platform for mid-sized, knowledge-based companies to thrive under one umbrella, maintaining entrepreneurial freedom while benefiting from group resources and support. About Biotec GmbH: Founded in 1991 and based in Gütersloh and Mittweida, Germany, Biotec GmbH is a leading consultancy and environmental laboratory specializing in microbiological hygiene and occupational health. With over 25 years of expertise, we pioneer aerial hygiene solutions for diverse industrial and food industry clients. Our services include air hygiene testing, HVAC system inspections under VDI 6022 standards, and hygiene training. Biotec GmbH is committed to excellence, supporting clients with high-quality services and expert opinions to maintain safe and compliant environments. For more information, visit biotec-gmbh.de About CERTANIA: Under the umbrella of CERTANIA Holding GmbH, a new global market player is created in the field of Testing, Inspection & Certification as well as scientific, laboratory and compliance services. This group offers medium-sized partners a sustainable home for their life’s work. CERTANIA enables entrepreneurs and owners to further develop their companies with like-minded people, while continuing to preserve their entrepreneurial roots, corporate culture, brand, and values. For more information, visit certania.com July 10, 2024 GREENPEAK is proudly looking back to a successful first half-year 2024 We would like to thank all our business partners and our teams and look forward to a fantastic second half of the year. Posts navigation Older posts
August 20, 2024 BIOTEC joins CERTANIA The pioneer in microbiological and aerial hygiene joins the group. Munich/Gütersloh, August 20, 2024. Biotec GmbH, a leading consultancy and environmental laboratory specializing in microbiological hygiene and occupational health, has joined CERTANIA, a dynamic group known for its Testing, Inspection, and Certification services. This strategic integration marks a pivotal moment for Biotec GmbH, enhancing its ability to expand its environmental and hygiene solutions globally. Founded in 1991 and based in Gütersloh, Germany, Biotec GmbH has built a solid reputation over 25 years as a pioneer in aerial hygiene. Its clientele spans across industrial giants and prominent players in the food industry, relying on its expertise for comprehensive air hygiene testing and certification, drinking water analyses, and specialized hygiene training. By joining CERTANIA, Biotec GmbH aligns itself with a robust platform that supports its commitment to excellence. The partnership strengthens Biotec GmbH’s capabilities in optimizing hygiene-sensitive production processes and validating hospital cleaning and disinfection equipment to meet stringent hygiene standards. Under the leadership of the managing directors Dr. Andreas Bermpohl, Jörg Weißer and Frank Weißer, the Biotec management team retains independence while accessing the resources of the larger group, facilitating continued growth and service expansion. “We are thrilled to join CERTANIA, which allows us to amplify our impact in ensuring safe and compliant environments,” said Dr. Andreas Bermpohl, co-founder and managing director of Biotec GmbH. “This partnership not only enhances our service offerings but also reinforces our dedication to delivering high-quality solutions backed by rigorous scientific expertise.” Moritz Gruber, CEO and managing shareholder of CERTANIA, welcomes Biotec and extends the invitation to join this unique group to other entrepreneurs and owners of companies in the field of scientific, laboratory, and compliance services: “We provide an opportunity to put their company into a future-proof structure. It is our fundamental aim to build a group for the long run, where strong partner companies flourish, while retaining their identity. Biotec’s renowned expertise in microbiological hygiene perfectly complements CERTANIA’s focus on environmental and regulatory services. Together, we are well-positioned to support industries in maintaining safety and compliance standards amid evolving global challenges like the COVID19 pandemic.” CERTANIA’s ecosystem provides a platform for mid-sized, knowledge-based companies to thrive under one umbrella, maintaining entrepreneurial freedom while benefiting from group resources and support. About Biotec GmbH: Founded in 1991 and based in Gütersloh and Mittweida, Germany, Biotec GmbH is a leading consultancy and environmental laboratory specializing in microbiological hygiene and occupational health. With over 25 years of expertise, we pioneer aerial hygiene solutions for diverse industrial and food industry clients. Our services include air hygiene testing, HVAC system inspections under VDI 6022 standards, and hygiene training. Biotec GmbH is committed to excellence, supporting clients with high-quality services and expert opinions to maintain safe and compliant environments. For more information, visit biotec-gmbh.de About CERTANIA: Under the umbrella of CERTANIA Holding GmbH, a new global market player is created in the field of Testing, Inspection & Certification as well as scientific, laboratory and compliance services. This group offers medium-sized partners a sustainable home for their life’s work. CERTANIA enables entrepreneurs and owners to further develop their companies with like-minded people, while continuing to preserve their entrepreneurial roots, corporate culture, brand, and values. For more information, visit certania.com July 10, 2024 GREENPEAK is proudly looking back to a successful first half-year 2024 We would like to thank all our business partners and our teams and look forward to a fantastic second half of the year. Posts navigation Older posts
July 10, 2024 GREENPEAK is proudly looking back to a successful first half-year 2024 We would like to thank all our business partners and our teams and look forward to a fantastic second half of the year. Posts navigation Older posts